Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCHC is a monocarboxylic acid transport (MCT) inhibitor. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo; decreases glycolytic metabolism, migration, and invasion in U251 cells. Enhances the effect of antitumor agent temozolomide (Cat No. 2706). Blocks lactate efflux from glioma cells and sensitizes cells to irradiation.
CHC is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 189.17 |
公式 | C10H7NO3 |
储存 | Store at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 28166-41-8 |
PubChem ID | 5328791 |
InChI Key | AFVLVVWMAFSXCK-VMPITWQZSA-N |
Smiles | OC1=CC=C(/C=C(C#N)/C(O)=O)C=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 18.92 | 100 | |
ethanol | 3.78 | 20 |
以下数据基于产品分子量 189.17。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 5.29 mL | 26.43 mL | 52.86 mL |
5 mM | 1.06 mL | 5.29 mL | 10.57 mL |
10 mM | 0.53 mL | 2.64 mL | 5.29 mL |
50 mM | 0.11 mL | 0.53 mL | 1.06 mL |
参考文献是支持产品生物活性的出版物。
Miranda-Gonçalves et al (2013) Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro.Oncol. 15 172 PMID: 23258846
Fang et al (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol.Pharmacol. 70 2108 PMID: 17000864
Dimmer et al (2000) The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem.J. 350 219 PMID: 10926847
Colen et al (2006) Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery 59 1313 PMID: 17277695
If you know of a relevant reference for CHC, please let us know.
关键词: CHC, CHC supplier, a-cyano-4-OH-cinnamate, alpha-cyano-4-OH-cinnamate, CHC, monocarboxylic, acid, monocarboxylate, transporters, MCT, inhibitors, inhibits, lactate, pyruvate, glycolytic, metabolism, gliomas, antiangiogenesis, antitumoral, ACCA, á-cyano-4-hydroxy-cinnamic, Antiangiogenics, Monocarboxylate, Transporters, 5029, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 CHC 的部分引用包括:
Jang et al (2016) A branched-chain amino acid metabolite drives vascular fatty acid transport and causes Ins resistance. Nat Med 22 421 PMID: 26950361
Kelvin P et al (2021) MYC-mediated early glycolysis negatively regulates proinflammatory responses by controlling IRF4 in inflammatory macrophages. Cell Rep 35 109264 PMID: 34133930
Kevin N et al (2022) Amyloid-β42 stimulated hippocampal lactate release is coupled to glutamate uptake. Sci Rep 12 2775 PMID: 35177691
Dietmar et al (2020) Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1. J Cancer 11 479-487 PMID: 31897243
Keit Men et al (2020) A glycolytic shift in Schwann cells supports injured axons. Nat Neurosci 23 1215-1228 PMID: 32807950
您是否知道使用了 Tocris CHC 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review CHC and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.